



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

John BRASSIL et al.

Group Art Unit: 1651

Application No.: 10/768,167

Examiner:

S. SAUCIER

Filed: February 2, 2004

Docket No.: 040219.04

For:

APPARATUS AND METHOD FOR DETERMINING EFFECTS OF A SUBSTANCE ON

AN ORGAN

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- \bowtie This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- \boxtimes 2. In accordance with 37 CFR §1.98(a)(2)(ii), copies of any U.S. patents and patent application publications are not attached.

 \boxtimes 3. Reference $\underline{2}$ corresponds to reference $\underline{4}$.

Respectfully submitted,

William P. Berridge Registration No. 30,024

Christopher J. Wheeler Registration No. 60,738

WPB:CJW/clf

Date: August 31, 2007

OLIFF & BERRIDGE, PLC P.O. Box 19928 Alexandria, Virginia 22320 Telephone: (703) 836-6400 DEPOSIT ACCOUNT USE
AUTHORIZATION
Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461

Sheet 1 of 2

	-VA							
Form PTO-14 (REV. 1/06)	,			ATTY DOCKET NO. 040219.04			APPLICATION NO. 10/768,167	
INFORMATION DISCLOSURE STATEMENT								
(Use several sheets if necessary)				APPLICANT(S) John BRASSIL et al.				
				i 1		GROUP 1651		
		U.	S. PATEN	T DOCUMENTS				
Examiner Initials	Cite No.	Document Number	Da	ite	Name			
	1	5,494,822	02/27/1996		Sadri			
	2	5,989,918	11/23/1999 01/06/2004		Dietz et al.			
	3	6,673,594			Owen et al.			
		FORE	EIGN PATI	ENT DOC	UMENTS			
Examiner Initials	Cite No.	Document Number	Da	ate	Country		With English Abstract	With English Translation
	4	WO 98/09166	03/05/19	98	WIPO			
	5	EP 1 208 748 A1	08/24/2000		Europe			
			OTHER D	OCUME	NTS			
Examiner Initials								
	6 11/802,064, 05/18/2007, Curtis et al. 7 11/802,059, 05/18/2007, Curtis et al.							
8 11/598,800, 11/14/2006, Brassil et al.								
	9	"Human Data Before Human-Trials Improving Drug Discovery and Development Productivity with Ex Vivo Metrics," Katzenbach Partners LLC, 2005, pp. 1-22.						,"
"Perfusion of the isolated rat liver," Curtis, C.G. et al., Proceedings of the Physiological Society, 12/1970,						70, pp.14P-15	O, pp.14P-15P.	
	 "Degradation of [³H]Chondroitin 4-Sulphate and Re-utilization of the [³H]Hexosamine Component by the Isolated Perfused Rat Liver," Macnicholl, Alan D. et al., Biochem. J. (1980), Vol. 186, pp. 279-286. "Utilization by the Isolated Perfused Rat Liver of N-Acetyl-D-[1-¹⁴C]galactosamine and N-[³H]Acetyl D-galactosamine for the Biosynthesis of Glycoproteins," MacNicoll, Alan D. et al., Biochem. J (1978) Vol. 174, pp. 421-426. 						the Isolated P	erfused Rat
							ine for the	
"NMR study of the whole rat bile: the biliary excretion of 4-cyano-N, N-dimethyl aniline by an isolated perfus liver in situ," Ryan, David A. et al., Journal of Pharmaceutical & Biomedical Analysis, 1995, Vol. 13, No. 6,								
	14	"Liver as major organ of phenol detoxication?," Powell, G. et al., <i>Nature</i> , 11/15/1974, Vol. 252, pp. 234-235.						
4	15	"Oxidation of Sodium Sulphide by Rat Liver, Lungs and Kidney," Bartholomew, Terrence C. et al., <i>Biochemical Pharmacology</i> , 1980, Vol. 29, pp. 2431-2437.						
	16	"The metabolic sulphation of polyethyleneglycols by isolated perfused rat and guinea-pig livers", Roy, A. B. and Maggs, J. et al., Xenobiotica, 1987, Vol. 17, No. 6, pp. 725-732.						
	17	"Octan-2-sulphate degradation in the isolated perfused rat liver", Maggs, J. et al., <i>Biochemical Pharmacology</i> , 1984, Vol. 33, No. 5, pp. 827-829.						
18 Isolated Perfused Liver Technology for Studying Metabolic and Toxicological Problems, Powell, G.M. 1, pp. 53-86.							et al., 1989, Vol. 7, No.	
EXAMINER						DATE C	ONSIDERED	
Examiner:		citation considered, whether or not citation considered. Include copy of this form with				through cit	ation if not in	conformance

Date: August 31, 2007

Sheet	2	of	2	
-------	---	----	---	--

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE	ATTY DOCKET NO. 040219.04	APPLICATION NO. 10/768,167			
INFORMATION DISCLOSURE STATEMENT							
(Use several sheets if necessary)			APPLICANT(S) John BRASSIL et al.				
			FILING DATE February 2, 2004	GROUP 1651			
		OTHER E	OOCUMENTS				
Examiner Initials	Cite No.	(Including Author, Title,	or, Title, Date, Pertinent Pages, etc.)				
	19	"Organ Perfusion and Mass Spectrometry: A Time Medicinal Chemistry, 2002, Vol. 2, pp. 77-86.	usion and Mass Spectrometry: A Timely Merger for Drug Development," Curtis, C. Gerald et al., Current Topics in Chemistry, 2002, Vol. 2, pp. 77-86.				
	20	The Use of Isolated Perfused Organs, Curtis, C.	Use of Isolated Perfused Organs, Curtis, C. G. et al., pp. 295-302.				
	21	Predictive Models for Tissue Metabolism-Screening Using Organ Perfusion Methods," Curtis, G., CPSA Digest 2001, http://www.milestonedevelopment.com/CPSA/2001/day3oa3.html.					
	22		perfused rat kidney system after in vivo and in vitro application of S-(1,2-iyl)-L-cysteine," Ilinskaja, O. and Vamvakas, S., Arch Toxicol (1996), vol. 70,				
	23	A New Paradigm in Perfusion, http://res-del.com	igm in Perfusion, http://res-del.com/resources/AQIX_RS-I.pdf.				
	24	"The Rate of Induction of Hypothermic Arrest Determines the Outcome in a Swine Model of Lethal Hemorrhage," Alam, H. et al., The Journal of TRAUMA Injury, Infection, and Critical Care, 11/2004, Vol. 57, No. 5, pp. 961-969.					
EXAMINER				DATE CONSIDERED			
Examiner:		Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant					

Date: August 31, 2007